Valuation: Alcon

Market Cap 33.35B 29.21B 26.9B 24.97B 47.42B 3,181B 48.06B 322B 125B 1,562B 125B 122B 5,414B P/E 2026 *
31.7x
P/E 2027 * 24.7x
Enterprise Value 35.95B 31.48B 29B 26.92B 51.11B 3,429B 51.8B 347B 135B 1,683B 135B 132B 5,836B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.95x
Free-Float
97.36%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
Manager TitleAgeSince
Chief Executive Officer 60 01/07/2018
Director of Finance/CFO 58 08/04/2019
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 01/07/2018
Director/Board Member 63 01/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+17.75%0.00% - - 33.41B
+0.23%+5.57%-27.14%+2.06% 90.56B
-1.54%+2.28%-0.37%-22.28% 14.47B
+0.59%+5.35% - - 9.73B
+1.77%+15.47%-1.16%+613.01% 2.24B
-0.09%+6.85%-27.79%-64.99% 1.46B
+0.40%+16.15%+24.46%+2.05% 895M
-1.21%+7.19%-38.25%-28.95% 856M
-0.12%0.00%+48.26%-30.53% 784M
+0.31%-11.55% - - 640M
Average +0.07%+5.09%-3.14%+67.19% 13.51B
Weighted average by Cap. +0.12%+2.96%-22.29%+9.82%

Financials

2026 *2027 *
Net sales 11.14B 9.76B 8.99B 8.34B 15.84B 1,063B 16.05B 108B 41.86B 522B 41.84B 40.92B 1,808B 11.82B 10.35B 9.53B 8.85B 16.81B 1,127B 17.03B 114B 44.42B 553B 44.39B 43.41B 1,919B
Net income 1.11B 975M 898M 834M 1.58B 106B 1.6B 10.75B 4.19B 52.14B 4.18B 4.09B 181B 1.38B 1.21B 1.11B 1.03B 1.96B 132B 1.99B 13.32B 5.18B 64.6B 5.18B 5.07B 224B
Net Debt 2.6B 2.27B 2.09B 1.94B 3.69B 248B 3.74B 25.06B 9.75B 122B 9.75B 9.53B 421B 1.54B 1.35B 1.24B 1.15B 2.19B 147B 2.22B 14.87B 5.79B 72.13B 5.78B 5.66B 250B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA